Mike Havert, Ph.D. joined StrideBio as Vice President of Regulatory Affairs in June 2021. Dr. Havert has spent the past 19 working at the interface of cell and gene therapy and government regulation. Originally trained as a virologist, Dr. Havert is fluent in the design, development, and testing for many advanced therapy products. He currently serves on different policy and standard setting groups, including the ASGCT Regulatory Affairs committee and the USP Advanced Therapies (BIO5) Expert committees. His prior work experience includes roles in Regulatory Science at bluebird bio and the Gene Therapy Branch at FDA. Dr. Havert holds a PhD from the UW-Madison where he studied the molecular mechanisms of viral replication and a B.A. from Boston University.
Mike Havert, Ph.D.
Vice-President, Regulatory Affairs